Bicara Therapeutics Inc. Common Stock (BCAX) Financial Ratios
4 years of historical data (2022–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
3.34
↑+58% vs avg
5yr avg: 2.11
30Y Low1.9·High2.3
ROE
↑
-30.9%
↓+9% vs avg
5yr avg: -33.9%
30Y Low-52%·High-19%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BCAX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Bicara Therapeutics Inc. Common Stock currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Market Cap | $1.3B | $920M | $948M | — | — |
| Enterprise Value | $1.2B | $825M | $459M | — | — |
| P/E Ratio → | -9.74 | — | — | — | — |
| P/S Ratio | — | — | — | — | — |
| P/B Ratio | 3.34 | 2.29 | 1.93 | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
BCAX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
BCAX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -30.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| ROE | -30.9% | -30.9% | -19.1% | -51.7% | — |
| ROA | -27.6% | -27.6% | -16.9% | -43.2% | -564.6% |
| ROIC | -75.4% | -75.4% | -2129.3% | — | — |
| ROCE | -32.6% | -32.6% | -21.4% | -39.6% | — |
BCAX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $97M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | -0.24 | -0.99 | -1.05 | — |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -336.89 |
Net cash position: cash ($97M) exceeds total debt ($2M)
BCAX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Bicara Therapeutics Inc. Common Stock's current ratio of 14.58x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 15.32x to 14.58x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Current Ratio | 14.58 | 14.58 | 27.93 | 15.32 | 0.21 |
| Quick Ratio | 14.58 | 14.58 | 27.93 | 15.32 | 0.21 |
| Cash Ratio | 14.33 | 14.33 | 27.22 | 15.28 | 0.17 |
| Asset Turnover | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — |
BCAX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Bicara Therapeutics Inc. Common Stock does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $55M | $54M | $52M | $52M |
Peer Comparison
Compare BCAX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BCAXYou | $1B | -9.7 | — | — | — | — | -30.9% | -75.4% | — |
 IMVT | $8B | -13.8 | — | — | — | — | -64.8% | — | — |
 TGTX | $8B | 19.6 | 68.9 | — | 83.7% | 20.0% | 102.8% | 16.4% | 2.1 |
 ACLX | $7B | -28.3 | — | — | 70.0% | -1135.6% | -53.4% | -46.2% | — |
 ERAS | $5B | -34.3 | — | — | — | — | -33.3% | -27.9% | — |
 KYMR | $8B | -27.0 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 MGNX | $291M | -3.9 | — | — | 71.1% | -48.7% | -86.9% | -144.1% | — |
 XNCR | $1B | -11.3 | — | — | 91.6% | -141.4% | -14.0% | -16.3% | — |
 ALKS | $8B | 32.2 | 23.6 | 16.0 | 86.7% | 17.2% | 14.7% | 18.9% | 0.2 |
 RCUS | $3B | -8.3 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 AGEN | $127M | -894.1 | — | — | 29.6% | -18.0% | — | — | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 4 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
BCAX — Frequently Asked Questions
Quick answers to the most common questions about buying BCAX stock.
What is Bicara Therapeutics Inc. Common Stock's P/E ratio?
Bicara Therapeutics Inc. Common Stock's current P/E ratio is -9.7x. This places it at the 50th percentile of its historical range.
What is Bicara Therapeutics Inc. Common Stock's ROE?
Bicara Therapeutics Inc. Common Stock's return on equity (ROE) is -30.9%. The historical average is -33.9%.
Is BCAX stock overvalued?
Based on historical data, Bicara Therapeutics Inc. Common Stock is trading at a P/E of -9.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.